A cardinal feature of the immune system is its ability to generate an enormous number of different antibodies (approximately 100 million in the mouse). 1 Antibodies are classically identified by their antigen binding properties. A second method of describing antibodies serologically is by an analysis of their idiotypes. The variable (V) region of the immunoglobulin molecule was first shown to be antigenic by the injection of V region polypeptides into experimental animals.2 These antigenic determinants are known as idiotopes and collectively comprise the idiotype. The three dimensional shape of the idiotype may involve structures on either the heavy or light chains or both. Idiotypes can be divided into two main types based on their precise location within the variable region: (a) those located at the antigen binding site (known as paratopes) and (b) those adjacent to it (known as framework determinants). Antibodies (anti-idiotypes) may be raised against idiotypes in either the same or different species by suitable immunisation. Furthermore, it is evident that the immune system may provide its own anti-idiotypes. Anti-idiotypes binding to the paratope will inhibit binding of the antigen to antibodies bearing the homologous idiotype, whereas those against framework determinants will not usually do so. Idiotypes may be restricted to a particular immunoglobulin molecule-a private idiotype, or appear on antibodies of different antigen binding specificity-a common or public idiotype. Idiotypes represent the phenotypic products of variable (V) region genes, and analysis of idiotypes permits study of the genetic relation between antibodies.
Consideration of idiotype-anti-idiotype interactions led Jerne to propose the network theory. Modulation of the immune system with idiotypes or anti-idiotypes has been proposed as a therapeutic approach in the management of SLE. In lupus prone mice anti-idiotype administration has been shown to suppress both production of anti-DNA antibodies and nephritis. The effect was transient, however, and anti-DNA antibodies appeared that did not bear the idiotype.33 Zouali et al innoculated mice with syngeneic anti-DNA IgG and muramyl dipeptide (an immunoadjuvant) and found that anti-DNA antibody levels were suppressed and that an antiidiotype antibody specific for the injected IgG appeared.34 Conjugation of anti-idiotype to a cytotoxic agent (neocarzinostatin) has been shown to eliminate anti-DNA antibody producing cells in vivo.35 Similar results have been obtained in vitro using conjugates of the A chain of ricin and antiidiotype to inhibit antibody response to acetylcholine receptor.36 Down regulation of a group of public idiotypes, such as those recently identified on anti-DNA, anti-Ro, and anti-Sm antibodies,37 may be an effective means of down regulating autoantibody production. This response may provide the fine tuning needed by the immune system to rid itself of unwanted autoantibodies and provide a therapeutic approach without the dangers of conventional intensive immunosuppressive therapy. Perhaps plasma exchange coupled with passage of plasma over anti-idiotype columns could one day be a feasible proposition.
In conclusion, analysis of idiotypes and antiidiotypes is casting light on the genetic origins of 
